Woodline Partners LP Buys 26,956 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Woodline Partners LP boosted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 3.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 806,912 shares of the biotechnology company's stock after acquiring an additional 26,956 shares during the period. Woodline Partners LP owned 2.98% of Arcturus Therapeutics worth $13,693,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of ARCT. Virtus ETF Advisers LLC grew its holdings in Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after acquiring an additional 1,132 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Arcturus Therapeutics during the 4th quarter worth $71,000. National Bank of Canada FI grew its holdings in Arcturus Therapeutics by 639.6% during the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock worth $94,000 after acquiring an additional 4,784 shares during the period. Kennedy Capital Management LLC grew its holdings in Arcturus Therapeutics by 22.7% during the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock worth $186,000 after acquiring an additional 2,036 shares during the period. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Arcturus Therapeutics during the 4th quarter worth $200,000. Institutional investors and hedge funds own 94.54% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on ARCT shares. Canaccord Genuity Group lowered their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a research report on Monday, March 10th. Citigroup reissued a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Finally, Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $57.80.

Arcturus Therapeutics Stock Up 1.4%

ARCT traded up $0.17 during trading on Tuesday, hitting $12.37. The company had a trading volume of 84,762 shares, compared to its average volume of 449,998. The company has a market capitalization of $335.35 million, a PE ratio of -5.56 and a beta of 2.36. Arcturus Therapeutics Holdings Inc. has a one year low of $8.04 and a one year high of $45.00. The firm's 50-day moving average price is $11.35 and its 200 day moving average price is $14.92.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. Sell-side analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.